Quick Answer
ARROWHEAD PHARMACEUTICALS, INC. reported Net Income of -$1.63 million for fiscal year 2025.
ARROWHEAD PHARMACEUTICALS, INC. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$1.63M | +99.7% |
| 2024 | -$599.49M | -192.0% |
| 2023 | -$205.28M | -16.6% |
| 2022 | -$176.06M | -25.0% |
| 2021 | -$140.85M | -66.6% |
| 2020 | -$84.55M | -224.4% |
| 2019 | $67.97M | +224.8% |
| 2018 | -$54.45M | -58.4% |
| 2017 | -$34.38M | +57.9% |
| 2016 | -$81.72M | +11.1% |
| 2015 | -$91.94M | -56.8% |
| 2014 | -$58.63M | -88.3% |
| 2013 | -$31.14M | -47.4% |
| 2012 | -$21.13M | -575.2% |
| 2011 | -$3.13M | +53.5% |
| 2005 | -$6.73M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $30.81M | +117.8% | +117.6% |
| June 30, 2025 | -$175.24M | -2.6% | -147.3% |
| March 31, 2025 | $370.44M | +395.6% | +314.0% |
| December 31, 2024 | -$173.09M | -30.3% | -1.3% |
| June 30, 2024 | -$170.79M | -65.9% | -36.3% |
| March 31, 2024 | -$125.30M | -357.4% | +5.7% |
| December 31, 2023 | -$132.86M | -221.5% | -29.1% |
| June 30, 2023 | -$102.95M | -42.9% | -311.5% |
- ARROWHEAD PHARMACEUTICALS, INC. showed an increase of +99.7% in Net Income compared to the prior fiscal year.
- Over the 2005–2025 period, ARROWHEAD PHARMACEUTICALS, INC.’s net income has grown by 75.8% (from -$6.73 million to -$1.63 million).
- The most recent figure is from ARROWHEAD PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on November 25, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: